87 related articles for article (PubMed ID: 15491773)
1. Re: ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma (92:31-39) by Lassus et al.
Marzano R; Orlandi G; Corrado G
Gynecol Oncol; 2004 Nov; 95(2):416-7; author reply 417-8. PubMed ID: 15491773
[No Abstract] [Full Text] [Related]
2. [Study of the amplification and expression of c-erbB2 oncogene in epithelial ovarian tumors].
Hou Y; Wang M; Liu W
Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):426-8. PubMed ID: 9387293
[TBL] [Abstract][Full Text] [Related]
3. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.
Lassus H; Leminen A; Vayrynen A; Cheng G; Gustafsson JA; Isola J; Butzow R
Gynecol Oncol; 2004 Jan; 92(1):31-9. PubMed ID: 14751135
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma].
Ren YL; Wang HY; Zhou XY; Shan BE; Yang WT; Shen L; Shi DR
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):367-71. PubMed ID: 20646447
[TBL] [Abstract][Full Text] [Related]
6. How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified?
Press MF
Am J Clin Pathol; 2006 Nov; 126(5):673-4. PubMed ID: 17050063
[No Abstract] [Full Text] [Related]
7. [Advances in the research of neu proto-oncogene in ovarian cancer].
Li G; Jiao S
Zhonghua Fu Chan Ke Za Zhi; 1995 Mar; 30(3):176-9. PubMed ID: 7796652
[No Abstract] [Full Text] [Related]
8. [Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications].
Li J; Zhong M; Song LL; Su GD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):824-5. PubMed ID: 16793610
[TBL] [Abstract][Full Text] [Related]
9. [Amplification of C-erB2 gene in ovarian cancer].
Zhang GL; Zu KL; Yu SY
Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):401-3, 444. PubMed ID: 8001415
[TBL] [Abstract][Full Text] [Related]
10. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma.
Lassus H; Sihto H; Leminen A; Joensuu H; Isola J; Nupponen NN; Butzow R
J Mol Med (Berl); 2006 Aug; 84(8):671-81. PubMed ID: 16607561
[TBL] [Abstract][Full Text] [Related]
11. Detection of numerical aberration in chromosome 17 and c-erbB2 gene amplification in epithelial ovarian cancer using recently established dual color FISH.
Fukushi Y; Sato S; Yokoyama Y; Kudo K; Maruyama H; Saito Y
Eur J Gynaecol Oncol; 2001; 22(1):23-5. PubMed ID: 11321488
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
[TBL] [Abstract][Full Text] [Related]
13. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
14. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
Liu JF; Hirsch MS; Lee H; Matulonis UA
Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expression profiles in serous ovarian carcinoma.
Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
[TBL] [Abstract][Full Text] [Related]
16. [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
Zhong M; Li J; Ding YQ; Song LL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):665-7. PubMed ID: 17160949
[TBL] [Abstract][Full Text] [Related]
17. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
18. [The relation of peroxisome proliferator activated receptorbeta and Epithelial Ovarian Carcinoma].
Yang Y; Hou JQ; Ju HW; Yu ZH; Zhao ZW; Yang S; Yang HJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Jul; 23(7):630-2. PubMed ID: 17618585
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
